Difference between revisions of "SPECT Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
Line 33: Line 33:
  
 
==Profile Development==
 
==Profile Development==
 +
 +
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.05.10.docx | QIBA DRAFT Profile with tracked changes - {Dr. Miyaoka}]] ''May 10, 2016''
  
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.05.1.docx | QIBA DRAFT Profile with tracked changes - {Dr. Dewaraja}]] ''May 1, 2016''
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.05.1.docx | QIBA DRAFT Profile with tracked changes - {Dr. Dewaraja}]] ''May 1, 2016''

Revision as of 22:09, 11 May 2016

Co-chairs: <Name; Name; as needed>
Secretary: <Staff Name>
Roster: (Roster)

Project Snapshot

The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.


Under consideration:

  • quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
  • quantifying organs, like the liver, for dosimetry as potential use cases


Established Task Forces Currently Working Toward a first Profile with title as follows below:

Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease

  • Image Acquisition and Image Processing for DaTscan – Dr. Dewaraja
  • Quantitative / Image Analysis – Drs. Miyaoka and Seibyl
  • Phantoms / DRO Group – Drs. Dickson and Zimmerman
  • Clinical / Literature Review – Dr. Seibyl

Meetings/Call Summaries


Working Documents

Literature Review (Profile 1.0)

Profile Development

Archived versions of the Profile

Statistical Reference Documents

Workflow Documents

Reference Materials